CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

Research output: Contribution to journalJournal articlepeer-review

Standard

CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. / Christensen, Dennis; Foged, Camilla; Rosenkrands, Ida; Lundberg, Carina Vingsbo; Andersen, Peter; Agger, Else Marie; Nielsen, Hanne Mørck.

In: Internation Journal of Pharmaceutics, Vol. 390, 2010, p. 19-24.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Christensen, D, Foged, C, Rosenkrands, I, Lundberg, CV, Andersen, P, Agger, EM & Nielsen, HM 2010, 'CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations', Internation Journal of Pharmaceutics, vol. 390, pp. 19-24. https://doi.org/10.1016/j.ijpharm.2009.10.043

APA

Christensen, D., Foged, C., Rosenkrands, I., Lundberg, C. V., Andersen, P., Agger, E. M., & Nielsen, H. M. (2010). CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Internation Journal of Pharmaceutics, 390, 19-24. https://doi.org/10.1016/j.ijpharm.2009.10.043

Vancouver

Christensen D, Foged C, Rosenkrands I, Lundberg CV, Andersen P, Agger EM et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Internation Journal of Pharmaceutics. 2010;390:19-24. https://doi.org/10.1016/j.ijpharm.2009.10.043

Author

Christensen, Dennis ; Foged, Camilla ; Rosenkrands, Ida ; Lundberg, Carina Vingsbo ; Andersen, Peter ; Agger, Else Marie ; Nielsen, Hanne Mørck. / CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. In: Internation Journal of Pharmaceutics. 2010 ; Vol. 390. pp. 19-24.

Bibtex

@article{c13ff1a0785911df928f000ea68e967b,
title = "CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations",
abstract = "Mucosal administration of vaccines has many advantages compared to parenteral vaccination. Needle-free mucosal vaccination would be easily applicable, target the vaccine to the entry point of many pathogens, and reduce the risk of infection with other pathogens during vaccination as compared to invasive methods.CAF01 is a novel liposome-based vaccine adjuvant with remarkable immunostimulatory activity. The potential of CAF01 liposomes as adjuvant for mucosal vaccines was investigated using the Calu-3 epithelial cell culture in vitro model. Thus, the mucosal permeability of the antigen as well as the epithelial integrity and the metabolic activity of the well-differentiated cells were investigated after exposure to CAF01. Finally, the adjuvant was tested for nasal administration in mice, combined with an influenza vaccine.The results suggest that CAF01 enhanced transport of antigen through the mucus layer on Calu-3 cells, increasing the concentration of antigen in the cell layer, as well as the transport across the epithelial cells. Furthermore CAF01 was well tolerated by the Calu-3 cells and the in vivo studies demonstrated increased cell-mediated immunity (CMI) as well as humoral immune responses in mice after nasal application of the influenza vaccine when combined with CAF01. CAF01 is thus a promising adjuvant for mucosal delivery.",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "Dennis Christensen and Camilla Foged and Ida Rosenkrands and Lundberg, {Carina Vingsbo} and Peter Andersen and Agger, {Else Marie} and Nielsen, {Hanne M{\o}rck}",
year = "2010",
doi = "10.1016/j.ijpharm.2009.10.043",
language = "English",
volume = "390",
pages = "19--24",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

AU - Christensen, Dennis

AU - Foged, Camilla

AU - Rosenkrands, Ida

AU - Lundberg, Carina Vingsbo

AU - Andersen, Peter

AU - Agger, Else Marie

AU - Nielsen, Hanne Mørck

PY - 2010

Y1 - 2010

N2 - Mucosal administration of vaccines has many advantages compared to parenteral vaccination. Needle-free mucosal vaccination would be easily applicable, target the vaccine to the entry point of many pathogens, and reduce the risk of infection with other pathogens during vaccination as compared to invasive methods.CAF01 is a novel liposome-based vaccine adjuvant with remarkable immunostimulatory activity. The potential of CAF01 liposomes as adjuvant for mucosal vaccines was investigated using the Calu-3 epithelial cell culture in vitro model. Thus, the mucosal permeability of the antigen as well as the epithelial integrity and the metabolic activity of the well-differentiated cells were investigated after exposure to CAF01. Finally, the adjuvant was tested for nasal administration in mice, combined with an influenza vaccine.The results suggest that CAF01 enhanced transport of antigen through the mucus layer on Calu-3 cells, increasing the concentration of antigen in the cell layer, as well as the transport across the epithelial cells. Furthermore CAF01 was well tolerated by the Calu-3 cells and the in vivo studies demonstrated increased cell-mediated immunity (CMI) as well as humoral immune responses in mice after nasal application of the influenza vaccine when combined with CAF01. CAF01 is thus a promising adjuvant for mucosal delivery.

AB - Mucosal administration of vaccines has many advantages compared to parenteral vaccination. Needle-free mucosal vaccination would be easily applicable, target the vaccine to the entry point of many pathogens, and reduce the risk of infection with other pathogens during vaccination as compared to invasive methods.CAF01 is a novel liposome-based vaccine adjuvant with remarkable immunostimulatory activity. The potential of CAF01 liposomes as adjuvant for mucosal vaccines was investigated using the Calu-3 epithelial cell culture in vitro model. Thus, the mucosal permeability of the antigen as well as the epithelial integrity and the metabolic activity of the well-differentiated cells were investigated after exposure to CAF01. Finally, the adjuvant was tested for nasal administration in mice, combined with an influenza vaccine.The results suggest that CAF01 enhanced transport of antigen through the mucus layer on Calu-3 cells, increasing the concentration of antigen in the cell layer, as well as the transport across the epithelial cells. Furthermore CAF01 was well tolerated by the Calu-3 cells and the in vivo studies demonstrated increased cell-mediated immunity (CMI) as well as humoral immune responses in mice after nasal application of the influenza vaccine when combined with CAF01. CAF01 is thus a promising adjuvant for mucosal delivery.

KW - Former Faculty of Pharmaceutical Sciences

U2 - 10.1016/j.ijpharm.2009.10.043

DO - 10.1016/j.ijpharm.2009.10.043

M3 - Journal article

C2 - 19879346

VL - 390

SP - 19

EP - 24

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

ER -

ID: 20319993